JPWO2019243801A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019243801A5 JPWO2019243801A5 JP2020570158A JP2020570158A JPWO2019243801A5 JP WO2019243801 A5 JPWO2019243801 A5 JP WO2019243801A5 JP 2020570158 A JP2020570158 A JP 2020570158A JP 2020570158 A JP2020570158 A JP 2020570158A JP WO2019243801 A5 JPWO2019243801 A5 JP WO2019243801A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- agent
- grem1
- gremlin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 22
- 201000011510 cancer Diseases 0.000 claims 20
- 239000002246 antineoplastic agent Substances 0.000 claims 15
- 102100038367 Gremlin-1 Human genes 0.000 claims 11
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 229940127089 cytotoxic agent Drugs 0.000 claims 7
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 6
- 229940041181 antineoplastic drug Drugs 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010061825 Duodenal neoplasm Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 206010054184 Small intestine carcinoma Diseases 0.000 claims 1
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000008873 bone osteosarcoma Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 229960002204 daratumumab Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 201000000312 duodenum cancer Diseases 0.000 claims 1
- 229960004137 elotuzumab Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229960003323 siltuximab Drugs 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000002471 spleen cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1809946.5A GB201809946D0 (en) | 2018-06-18 | 2018-06-18 | Prevention and treatment of cancer |
| GB1809946.5 | 2018-06-18 | ||
| GB1815694.3 | 2018-09-26 | ||
| GBGB1815694.3A GB201815694D0 (en) | 2018-09-26 | 2018-09-26 | Prevention and treatment of cancer |
| PCT/GB2019/051699 WO2019243801A1 (en) | 2018-06-18 | 2019-06-18 | Gremlin-1 antagonist for the prevention and treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528400A JP2021528400A (ja) | 2021-10-21 |
| JPWO2019243801A5 true JPWO2019243801A5 (enExample) | 2022-06-10 |
| JP7565219B2 JP7565219B2 (ja) | 2024-10-10 |
Family
ID=67107908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570158A Active JP7565219B2 (ja) | 2018-06-18 | 2019-06-18 | がんを予防及び治療するためのｇｒｅｍｌｉｎ－１アンタゴニスト |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12162934B2 (enExample) |
| EP (1) | EP3806898B1 (enExample) |
| JP (1) | JP7565219B2 (enExample) |
| KR (1) | KR20210028191A (enExample) |
| CN (1) | CN112533632A (enExample) |
| AU (1) | AU2019289176B2 (enExample) |
| BR (1) | BR112020025661A2 (enExample) |
| CA (1) | CA3102743A1 (enExample) |
| CL (1) | CL2020003249A1 (enExample) |
| CO (1) | CO2020015923A2 (enExample) |
| DK (1) | DK3806898T3 (enExample) |
| ES (1) | ES3054944T3 (enExample) |
| FI (1) | FI3806898T3 (enExample) |
| HR (1) | HRP20251604T1 (enExample) |
| IL (1) | IL279347B1 (enExample) |
| LT (1) | LT3806898T (enExample) |
| MX (1) | MX2020013808A (enExample) |
| PL (1) | PL3806898T3 (enExample) |
| PT (1) | PT3806898T (enExample) |
| SG (1) | SG11202012312UA (enExample) |
| SI (1) | SI3806898T1 (enExample) |
| WO (1) | WO2019243801A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| GB201802486D0 (en) | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
| PT3806898T (pt) | 2018-06-18 | 2025-12-02 | UCB Biopharma SRL | Antagonista de gremlin-1 para utilização no tratamento do cancro |
| US20250270302A1 (en) | 2020-10-20 | 2025-08-28 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof |
| KR20230132544A (ko) * | 2021-01-18 | 2023-09-15 | 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 | 신규한 항-그렘린1 항체 |
| TW202300527A (zh) * | 2021-03-11 | 2023-01-01 | 上海交通大學 | 使用ｇｒｅｍ１拮抗劑治療疾病的方法 |
| GB202205203D0 (en) | 2022-04-08 | 2022-05-25 | UCB Biopharma SRL | Combination with inhibitor |
| GB202205200D0 (en) | 2022-04-08 | 2022-05-25 | Ucb Biopharma Sprl | Combination with chemotherapy |
| WO2023203177A1 (en) | 2022-04-20 | 2023-10-26 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof |
| WO2024026505A2 (en) * | 2022-07-29 | 2024-02-01 | Amit Patel | Disruption of telocyte activity |
| WO2024213066A1 (en) * | 2023-04-13 | 2024-10-17 | Suzhou Transcenta Therapeutics Co., Ltd. | Combination therapies involving grem1 antagonists for treatment of cancer |
| WO2026027660A1 (en) | 2024-08-02 | 2026-02-05 | UCB Biopharma SRL | Formulations of anti-gremlin-1 antibodies |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1541682A3 (en) | 1988-09-02 | 2005-07-06 | Dyax Corp. | Generation and selection of recombinant varied binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| DE69531148T2 (de) | 1994-01-31 | 2004-04-29 | Trustees Of Boston University, Boston | Bibliotheken aus polyklonalen antikörpern |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US20020159986A1 (en) | 2001-01-12 | 2002-10-31 | John Langenfeld | Bone morphogenetic protein-2 in the treatment and diagnosis of cancer |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| JP4603894B2 (ja) | 2002-12-03 | 2010-12-22 | ユセベ ファルマ ソシエテ アノニム | 抗体産生細胞を同定するためのアッセイ |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| AU2004253738A1 (en) | 2003-07-01 | 2005-01-13 | Ucb Pharma S.A. | Modified antibody Fab fragments |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| EP2325339A3 (en) | 2003-09-09 | 2011-11-02 | Integrigen, Inc. | Methods and compositions for generation of germline human antibody genes |
| EP1571159A1 (en) | 2004-03-04 | 2005-09-07 | Bayerische Julius-Maximilians-Universität Würzburg | Mutein of a bone morphogenetic protein and use thereof |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| US20090203041A1 (en) | 2006-04-21 | 2009-08-13 | Wei Shi | Bmp4 inhibitors |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| US8383349B2 (en) * | 2007-03-16 | 2013-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Bone morphogenetic protein antagonist and uses thereof |
| JP5592792B2 (ja) | 2007-09-26 | 2014-09-17 | ユセベ ファルマ ソシエテ アノニム | 二重特異性抗体の融合体 |
| EP2826790B1 (en) | 2012-03-15 | 2019-02-13 | SNU R&DB Foundation | Anti-gremlin-1 antibody |
| CN105189548A (zh) * | 2013-03-14 | 2015-12-23 | 瑞泽恩制药公司 | Grem1的人抗体 |
| US9878994B2 (en) * | 2014-07-24 | 2018-01-30 | Beta Pharma Inc. | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof |
| CN111170998B (zh) * | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| US10590111B2 (en) * | 2014-12-11 | 2020-03-17 | Beta Pharma, Inc. | Substituted 2-anilinopyrimidine derivatives as EGFR modulators |
| GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| MX2019015177A (es) * | 2017-06-16 | 2020-02-07 | Beta Pharma Inc | Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas. |
| WO2019148161A1 (en) * | 2018-01-29 | 2019-08-01 | Beta Pharma, Inc. | 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof |
| GB201802486D0 (en) | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
| PT3806898T (pt) | 2018-06-18 | 2025-12-02 | UCB Biopharma SRL | Antagonista de gremlin-1 para utilização no tratamento do cancro |
-
2019
- 2019-06-18 PT PT197344609T patent/PT3806898T/pt unknown
- 2019-06-18 BR BR112020025661-7A patent/BR112020025661A2/pt unknown
- 2019-06-18 US US17/253,660 patent/US12162934B2/en active Active
- 2019-06-18 HR HRP20251604TT patent/HRP20251604T1/hr unknown
- 2019-06-18 AU AU2019289176A patent/AU2019289176B2/en active Active
- 2019-06-18 CN CN201980041089.7A patent/CN112533632A/zh active Pending
- 2019-06-18 KR KR1020217001142A patent/KR20210028191A/ko active Pending
- 2019-06-18 CA CA3102743A patent/CA3102743A1/en active Pending
- 2019-06-18 PL PL19734460.9T patent/PL3806898T3/pl unknown
- 2019-06-18 MX MX2020013808A patent/MX2020013808A/es unknown
- 2019-06-18 SI SI201930994T patent/SI3806898T1/sl unknown
- 2019-06-18 DK DK19734460.9T patent/DK3806898T3/da active
- 2019-06-18 WO PCT/GB2019/051699 patent/WO2019243801A1/en not_active Ceased
- 2019-06-18 SG SG11202012312UA patent/SG11202012312UA/en unknown
- 2019-06-18 FI FIEP19734460.9T patent/FI3806898T3/fi active
- 2019-06-18 JP JP2020570158A patent/JP7565219B2/ja active Active
- 2019-06-18 EP EP19734460.9A patent/EP3806898B1/en active Active
- 2019-06-18 ES ES19734460T patent/ES3054944T3/es active Active
- 2019-06-18 LT LTEPPCT/GB2019/051699T patent/LT3806898T/lt unknown
-
2020
- 2020-12-10 IL IL279347A patent/IL279347B1/en unknown
- 2020-12-15 CL CL2020003249A patent/CL2020003249A1/es unknown
- 2020-12-17 CO CONC2020/0015923A patent/CO2020015923A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9150650B2 (en) | Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof | |
| ES2469369T3 (es) | Anticuerpos anti-CXCR4 humanizados para el tratamiento del cáncer | |
| AU2011243958B2 (en) | Molecules and methods of using same for treating ErbB/ErbB ligands associated diseases | |
| US8580258B2 (en) | Treatment of tumors using specific anti-L1 antibody | |
| JP2015517300A5 (enExample) | ||
| KR20180133399A (ko) | 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체 | |
| JP2010233575A (ja) | 新規抗ｉｇｆ−ｉｒ抗体およびその使用 | |
| JP2009024014A (ja) | 癌に対する抗体 | |
| CA2786479A1 (en) | Methods for treating pancreatic cancer | |
| JP2014524902A5 (enExample) | ||
| ES2759329T3 (es) | Anticuerpos contra la anfirregulina, composiciones que los comprenden y usos de los mismos | |
| JP2022532784A (ja) | 抗ｃｌｄｎ抗体並びにその医薬組成物および検出方法 | |
| WO2015076425A1 (ja) | 新規モノクローナル抗体 | |
| JPWO2019243801A5 (enExample) | ||
| AU2015280436A1 (en) | Antibodies that bind LGR4 | |
| JP2020505075A5 (enExample) | ||
| KR20230156936A (ko) | 그렘린1 길항제를 사용하여 질환을 치료하는 방법 | |
| JP6041333B2 (ja) | 抗腫瘍剤 | |
| JP2021524032A (ja) | Ｇａｓｐ−１顆粒を標的とする結合性タンパク質及びキメラ抗原受容体ｔ細胞並びにそれらの使用 | |
| JP7438560B2 (ja) | Ｓｍｏタンパク質の特異的エピトープ、これを認知する抗体及びこれを含む組成物 | |
| CN111018989A (zh) | 一种抗pd-l1单克隆抗体以及在制备抗癌药物方面的应用 | |
| RU2020142709A (ru) | Антагонист gremlin-1 для предупреждения и лечения рака | |
| KR102207221B1 (ko) | 도펠-타겟팅 분자를 이용한 병리학적 신생혈관 생성을 억제하는 방법 | |
| WO2024241997A1 (ja) | がんを治療又は予防するための医薬組成物 | |
| JP6701382B2 (ja) | 上皮成長因子受容体に特異的に結合する抗体を有効成分として含む、癌の転移を抑制するための医薬組成物 |